Genfit S.A. (LON:0QT6)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 384.06M +184.4% |
| Revenue (ttm) | 61.80M +0.2% |
| Net Income | -75.00M |
| EPS | -1.50 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,729 |
| Open | 8.99 |
| Previous Close | 9.13 |
| Day's Range | 8.71 - 8.99 |
| 52-Week Range | 3.06 - 15.46 |
| Beta | 1.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 29, 2026 |
About Genfit
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, which is in Phase 1b clinical trial for the treatment of cholangiocarcin... [Read more]
News
Genfit Slides: H.C. Wainwright 28th Annual Global Investment Conference presentation
Genfit has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Genfit Transcript: KOL event
The event highlighted the urgent need for scalable, accurate MASH diagnostics as new therapies shift the market focus to patient identification and monitoring. NIS2+ is validated as a superior, non-invasive test, with strong clinical and commercial prospects, supported by pharma partnerships and a robust roadmap to global adoption.
Genfit Press release: KOL event
Genfit issued a press release on September 9, 2026, disclosing material business information to investors.
Genfit Slides: KOL event
Genfit has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Genfit Slides: Corporate presentation
Genfit has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
Investigational drug GNS561 showed a favorable safety and tolerability profile in a Phase 1b study evaluating its potential in combination with a MEK inhibitor (MEKi) Study conducted in a heavily pret...
GENFIT: June 15, 2026 Combined Shareholders Meeting Results
All resolutions recommended by the Board of Directors approved (quorum: 32.13 %) Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); June 15, 2026 - GENFIT (Euronext: GNF...
GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp's OnDemand Offering for Identification of At-Risk MASH
Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH This model expands access and supp...
Genfit Earnings release: Q1 2026
Genfit released its Q1 2026 earnings on May 21, 2026, summarizing the period's financial results.
Genfit Slides: Investor presentation
Genfit has posted slides in relation to its latest quarterly earnings report, which was published on April 24, 2026.
Genfit Annual report: Q4 2025
Genfit has published its Q4 2025 annual report on April 2, 2026.
Genfit Earnings release: Q4 2025
Genfit released its Q4 2025 earnings on April 2, 2026, summarizing the period's financial results.
Genfit Earnings release: Q4 2025
Genfit released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Genfit Earnings release: Q3 2025
Genfit released its Q3 2025 earnings on November 20, 2025, summarizing the period's financial results.